Drugs / alphagan-P
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ALPHAGAN P | — | 2001-12-20 | fda.gov ↗ |
| Approved | US (FDA) | ALPHAGAN P | — | 2001-03-16 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04296916 | Apr 2020 → Oct 2024 | borderline glaucoma, myopia | Sun Yat-sen University | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | alphagan-P | “alphagan 0.2% or alphagan-P 0.15% will be added.” NCT04296916 ↗ |